Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma

Askar Obulkasim, Bauke Ylstra, Hendrik F. van Essen, Christian Benner, Sally Stenning, Ruth Langley, William Allum, David Cunningham, Imran Inam, Lindsay C. Hewitt, Nicolas P. West, Gerrit A. Meijer, Mark A. van de Wiel, Heike I. Grabsch*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)


Neoadjuvant chemo(radio) therapy followed by surgery is the standard of care for patients with locally advanced resectable esophageal adenocarcinoma (EAC). There is increasing evidence that drug resistance might be related to genomic heterogeneity. We investigated whether genomic tumor heterogeneity is different after cytotoxic chemotherapy and is associated with EAC patient survival. We used arrayCGH and a quantitative assessment of the whole genome DNA copy number aberration patterns ('DNA copy number entropy') to establish the level of genomic tumor heterogeneity in 80 EAC treated with neoadjuvant chemotherapy followed by surgery (CS group) or surgery alone (S group). The association between DNA copy number entropy, clinicopathological variables and survival was investigated. DNA copy number entropy was reduced after chemotherapy, even if there was no morphological evidence of response to therapy (p
Original languageEnglish
Pages (from-to)44084-44095
Number of pages12
Issue number28
Publication statusPublished - 12 Jul 2016


  • esophageal adenocarcinoma
  • array CGH
  • prognosis
  • chemotherapy

Cite this